We came across a bullish thesis on Moderna, Inc. on Alpha Talon Investment Research’s Substack by AT Investment Research. In this article, we will summarize the bulls’ thesis on MRNA. Moderna, Inc.'s share was trading at $29.92 as of December 15th. MRNA’s trailing P/E was 7.06 according to Yahoo Finance.
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. MRNA’s strategy from 2025–2030 emphasizes capital efficiency and asset optimization as the company transitions from pandemic-driven...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.